A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
This first-in-human open-label,dose-escalation study is designed to evaluate the safety,
tolerability, and primary efficacy of IBI321 in participants with locally advanced,
recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has
proven to be ineffective or intolerable.